CN Patent

CN119486713A — 尼罗加司他治疗

Assigned to Springworths Treatment Co ltd · Expires 2025-02-18 · 1y expired

What this patent protects

本公开涉及改进的尼罗加司他治疗方法。本发明还包括用尼罗加司他及其药学上可接受的盐治疗对γ分泌酶的抑制有响应的病症的改进方法，这些病症诸如为硬纤维瘤、多发性骨髓瘤、卵巢颗粒细胞瘤。

USPTO Abstract

本公开涉及改进的尼罗加司他治疗方法。本发明还包括用尼罗加司他及其药学上可接受的盐治疗对γ分泌酶的抑制有响应的病症的改进方法，这些病症诸如为硬纤维瘤、多发性骨髓瘤、卵巢颗粒细胞瘤。

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN119486713A
Jurisdiction: CN
Classification: —
Expires: 2025-02-18
Drug substance claim: No
Drug product claim: No
Assignee: Springworths Treatment Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.